Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 159

Sort by

Sort Order Select

Journal Articles

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Blood (2025) 146 (Supplement 1): 235.

https://doi.org/10.1182/blood-2025-235

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience

Blood (2025) 146 (Supplement 1): 3843.

https://doi.org/10.1182/blood-2025-3843

Published: 2025

Journal Articles

Repertoire of driver events in coding and non-coding regions identified by whole-genome sequencing of myeloid neoplasms

Blood (2025) 146 (Supplement 1): 1450.

https://doi.org/10.1182/blood-2025-1450

Published: 2025

Journal Articles

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Blood (2025) 146 (Supplement 1): 763.

https://doi.org/10.1182/blood-2025-763

Published: 2025

Journal Articles

Socioeconomic inequality in acute myeloid leukaemia treatment in England: What drives this inequality

Koki Shimizu, Mari Saito, Camille Maringe, Yasushi Miyazaki, Bernard Rachet

Blood (2025) 146 (Supplement 1): 6385.

https://doi.org/10.1182/blood-2025-6385

Published: 2025

Journal Articles

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.

Blood (2025) 146 (Supplement 1): 5546.

https://doi.org/10.1182/blood-2025-5546

Published: 2025

Journal Articles

A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study

Blood (2025) 146 (Supplement 1): 998.

https://doi.org/10.1182/blood-2025-998

Published: 2025

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults

Blood (2024) 144 (Supplement 1): 2819.

https://doi.org/10.1182/blood-2024-199435

Published: 2024

Journal Articles

Molecular Taxonomy Classification for Transplant Decision Making of Myelodysplastic Syndromes

Rurika Okuda, Yotaro Ochi, Tetsuichi Yoshizato, Yasuhito Nannya, Yoshiko Atsuta, Yuichi Shiraishi, Yusuke Shiozawa, Hiroko Tanaka, Makoto Onizuka, Kenichi Chiba, Hidehiro Itonaga, Yoshinobu Kanda, Yasushi Miyazaki, Keizo Horibe, Satoru Miyano, Hideki Makishima, Seishi Ogawa

Blood (2024) 144 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2024-206498

Published: 2024

Journal Articles

Optimal Procedures of Allogeneic Transplantation for BCR::ABL1 -Negative Atypical Chronic Myeloid Leukemia

Hidehiro Itonaga, Yasushi Miyazaki, Takeshi Kondo, Yutaka Shimazu, Jun Aoki, Shuhei Kurosawa, Takashi Ikeda, Tetsuya Eto, Naoyuki Uchida, Hideyuki Nakazawa, Koji Kawamura, Junya Kanda, Yoshiko Atsuta, Takayoshi Tachibana

Blood (2024) 144 (Supplement 1): 4548.

https://doi.org/10.1182/blood-2024-193697

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

Prognostic Impact of Graft-Versus-Host Disease on Allogeneic Transplantation for CMML Focusing on Conditioning Intensity

Hidehiro Itonaga, Yasushi Miyazaki, Machiko Fujioka, Shuhei Kurosawa, Yasunobu Nagata, Yutaka Shimazu, Tomoaki Ueda, Naoyuki Uchida, Noriko Doki, Tetsuya Nishida, Ken-ichi Matsuoka, Masatsugu Tanaka, Makoto Yoshimitsu, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Takayoshi Tachibana

Blood (2024) 144 (Supplement 1): 6755.

https://doi.org/10.1182/blood-2024-193699

Published: 2024

Journal Articles

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Blood (2024) 144 (Supplement 1): 1332.

https://doi.org/10.1182/blood-2024-194024

Published: 2024

Journal Articles

Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children's Cancer Group and Japan Adult Leukemia Study Group

Blood (2024) 144 (Supplement 1): 1426.

https://doi.org/10.1182/blood-2024-199500

Published: 2024

Journal Articles

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

Amer M. Zeidan, Pierre Fenaux, Xia Han, David A. James, Kamel Malek, Pedro Marques Ramos, Yasushi Miyazaki, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 3236.

https://doi.org/10.1182/blood-2023-180765

Published: 2023

Journal Articles

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Yoshihiro Hatta, Fumihiko Hayakawa, Etsuko Yamazaki, Tohru Murayama, Takeshi Saito, Satoru Takada, Nobuaki Dobashi, Shuichi Ota, Yasuhisa Yokoyama, Masatsugu Tanaka, Shinya Sato, Shigeki Ohtake, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Itaru Matsumura, Yasushi Miyazaki, Hitoshi Kiyoi

Blood (2023) 142 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2023-178332

Published: 2023

Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Blood (2023) 142 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2023-179252

Published: 2023

Journal Articles

Impact of Conditioning Intensity and Regimen on Outcomes after Unrelated Cord Blood Transplantation for Patients with Myelodysplastic Syndrome

Machiko Fujioka, Hidehiro Itonaga, Yasushi Miyazaki, Yoshimitsu Shimomura, Naoyuki Uchida, Satoshi Takahashi, Makoto Onizuka, Yasunori Ueda, Yasufumi Uehara, Masatsugu Tanaka, Yoshiko Matsuhashi, Shigesaburo Miyakoshi, Haruyuki Tanaka, Toshiro Kawakita, Fumihiko Ishimaru, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Ken Ishiyama

Blood (2023) 142 (Supplement 1): 3536.

https://doi.org/10.1182/blood-2023-179157

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience

Repertoire of driver events in coding and non-coding regions identified by whole-genome sequencing of myeloid neoplasms

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Socioeconomic inequality in acute myeloid leukaemia treatment in England: What drives this inequality

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.

A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults

Molecular Taxonomy Classification for Transplant Decision Making of Myelodysplastic Syndromes

Optimal Procedures of Allogeneic Transplantation for BCR::ABL1 -Negative Atypical Chronic Myeloid Leukemia

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Prognostic Impact of Graft-Versus-Host Disease on Allogeneic Transplantation for CMML Focusing on Conditioning Intensity

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children's Cancer Group and Japan Adult Leukemia Study Group

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Impact of Conditioning Intensity and Regimen on Outcomes after Unrelated Cord Blood Transplantation for Patients with Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only